Bora Pharmaceuticals to Acquire MacroGenics CDMO Business for $122.5M

Deal Summary

Bora Pharmaceuticals announced that its Board of Directors approved the acquisition of MacroGenics Inc.'s CDMO business for a total consideration of $122.5 million, expanding its biologics CDMO platform and increasing its 12‑month rolling backlog to about $375 million.